CASTLE BIOSCIENCES, INC. Cost of Revenue
CASTLE BIOSCIENCES, INC. (CSTL) reported Cost of Revenue of $23.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement
us-gaap:CostOfRevenue · last filed 2026-07-30
- CASTLE BIOSCIENCES, INC. cost of revenue for the quarter ending 2026-06-30 was $23.70M, a 34.46% increase year-over-year.
- CASTLE BIOSCIENCES, INC. cost of revenue for the quarter ending 2026-03-31 was $20.53M, a 25.33% increase year-over-year.
- CASTLE BIOSCIENCES, INC. cost of revenue for the quarter ending 2025-12-31 was $18.32M, a 13.17% increase year-over-year.
- CASTLE BIOSCIENCES, INC. cost of revenue for the quarter ending 2025-09-30 was $18.70M, a 19.83% increase year-over-year.
- CASTLE BIOSCIENCES, INC. cost of revenue for fiscal 2025 was $71.03M, a 17.98% increase from fiscal 2024.
- CASTLE BIOSCIENCES, INC. cost of revenue for fiscal 2024 was $60.20M, a 33.84% increase from fiscal 2023.
- CASTLE BIOSCIENCES, INC. cost of revenue for fiscal 2023 was $44.98M, a 40.53% increase from fiscal 2022.
- CASTLE BIOSCIENCES, INC. cost of revenue for fiscal 2022 was $32.01M, a 102.31% increase from fiscal 2021.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | $23.70M 10-Q · filed 2026-07-30 | $44.23M 10-Q · filed 2026-07-30 | $62.55M derived: sum of 3 quarters · filed 2026-07-30 | $81.25M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $20.53M 10-Q · filed 2026-05-06 | $38.85M derived: sum of 2 quarters · filed 2026-05-06 | $57.55M derived: sum of 3 quarters · filed 2026-05-06 | $75.18M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $18.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $37.02M derived: sum of 2 quarters · filed 2026-02-26 | $54.65M derived: sum of 3 quarters · filed 2026-07-30 | $71.03M 10-K · filed 2026-02-26 |
| 2025-09-30 | $18.70M 10-Q · filed 2025-11-03 | $36.33M derived: sum of 2 quarters · filed 2026-07-30 | $52.71M 10-Q · filed 2025-11-03 | $68.90M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $17.63M 10-Q · filed 2026-07-30 | $34.01M 10-Q · filed 2026-07-30 | $50.19M derived: sum of 3 quarters · filed 2026-07-30 | $65.80M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $16.38M 10-Q · filed 2026-05-06 | $32.57M derived: sum of 2 quarters · filed 2026-05-06 | $48.17M derived: sum of 3 quarters · filed 2026-05-06 | $62.69M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $16.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $31.79M derived: sum of 2 quarters · filed 2026-02-26 | $46.31M derived: sum of 3 quarters · filed 2026-02-26 | $60.20M 10-K · filed 2026-02-26 |
| 2024-09-30 | $15.61M 10-Q · filed 2025-11-03 | $30.13M derived: sum of 2 quarters · filed 2025-11-03 | $44.02M 10-Q · filed 2025-11-03 | $56.45M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $14.52M 10-Q · filed 2025-08-04 | $28.41M 10-Q · filed 2025-08-04 | $40.84M derived: sum of 3 quarters · filed 2026-02-26 | $52.16M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $13.89M 10-Q · filed 2025-05-05 | $26.32M derived: sum of 2 quarters · filed 2026-02-26 | $37.64M derived: sum of 3 quarters · filed 2026-02-26 | $48.69M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $12.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $23.74M derived: sum of 2 quarters · filed 2026-02-26 | $34.80M derived: sum of 3 quarters · filed 2026-02-26 | $44.98M 10-K · filed 2026-02-26 |
| 2023-09-30 | $11.32M 10-Q · filed 2024-11-04 | $22.38M derived: sum of 2 quarters · filed 2024-11-04 | $32.56M 10-Q · filed 2024-11-04 | $42.08M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $11.06M 10-Q · filed 2024-08-05 | $21.24M 10-Q · filed 2024-08-05 | $30.76M derived: sum of 3 quarters · filed 2025-02-27 | $39.62M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $10.18M 10-Q · filed 2024-05-02 | $19.70M derived: sum of 2 quarters · filed 2025-02-27 | $28.56M derived: sum of 3 quarters · filed 2025-02-27 | $36.25M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $9.52M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $18.38M derived: sum of 2 quarters · filed 2025-02-27 | $26.07M derived: sum of 3 quarters · filed 2025-02-27 | $32.01M 10-K · filed 2025-02-27 |
| 2022-09-30 | $8.86M 10-Q · filed 2023-11-02 | $16.55M derived: sum of 2 quarters · filed 2023-11-02 | $22.49M 10-Q · filed 2023-11-02 | $27.09M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $7.69M 10-Q · filed 2023-08-02 | $13.63M 10-Q · filed 2023-08-02 | $18.23M derived: sum of 3 quarters · filed 2023-08-02 | $22.73M derived: sum of 4 quarters · filed 2023-08-02 |
| 2022-03-31 | $5.94M 10-Q · filed 2023-05-03 | $10.54M derived: sum of 2 quarters · filed 2023-05-03 | $15.04M derived: sum of 3 quarters · filed 2023-05-03 | $18.74M derived: sum of 4 quarters · filed 2023-05-03 |
| 2021-12-31 | $4.60M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $9.10M derived: sum of 2 quarters · filed 2023-02-28 | $12.79M derived: sum of 3 quarters · filed 2023-02-28 | $15.82M 10-K · filed 2023-02-28 |
| 2021-09-30 | $4.50M 10-Q · filed 2022-11-02 | $8.20M derived: sum of 2 quarters · filed 2022-11-02 | $11.22M 10-Q · filed 2022-11-02 | |
| 2021-06-30 | $3.70M 10-Q · filed 2022-08-08 | $6.72M 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $3.03M 10-Q · filed 2022-05-09 | |||
| 2020-09-30 | $2.48M 10-Q · filed 2021-11-08 | $4.62M derived: sum of 2 quarters · filed 2021-11-08 | $7.01M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $2.15M 10-Q · filed 2021-08-09 | $4.54M 10-Q · filed 2021-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B |